(Q39370687)

11 September 2017

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer (English)

1 reference

11 September 2017

1 reference

U H Stenman

1

1 reference

11 September 2017

M Hakama

2

1 reference

11 September 2017

P Knekt

3

1 reference

11 September 2017

A Aromaa

4

1 reference

11 September 2017

L Teppo

5

1 reference

11 September 2017

J Leinonen

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 December 1994

1 reference

11 September 2017

1 reference

11 September 2017

344

1 reference

11 September 2017

1594-1598

1 reference

11 September 2017

8937

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Pilot study of screening for prostate cancer in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Prostate cancer: to screen or not to screen?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Ethics of a prostate cancer screening trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Latent carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

The status of prostate cancer early detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Data quality and quality control of a population-based cancer registry. Experience in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

[Validation of the Düsseldorfer screening tool: a trait-based approach to assess psychological distress of cancer patients]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Prostate-specific antigen and prostate gland volume: Correlation and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

Clinical observations on the doubling time of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990405-7

7 January 2021

10.1016/S0140-6736(94)90405-7

Identifiers

DOI

1 reference

11 September 2017

1 reference